Checkpoint blockade therapy using anti-PD-1 and anti-CTLA-4 based drugs to inhibit tumor-mediated immunosuppression is proving to be a very powerful approach to treating some types of cancer [25]. This evidence concerns the gene CTLA4 and neoplasm.